Results
In the treatment group 95 patients died compared to 74.6 expected (SMR 1.27 (95% confidence interval 1.04-1.56)). In women mortality was higher than in men. After exclusion of high-risk patients, the SMR for CVD mortality remained increased in women. Mortality due to malignancies was not elevated. In the control groups mortality was not different from the background population. Univariate analyses demonstrated sex, GHD onset, age, and underlying diagnosis as influencing factors.
Conclusions
GHD men receiving GH treatment have a mortality rate not different from the background population. In women, after exclusion of high-risk patients, mortality was not different from the background population except for CVD. Mortality due to malignancies was not elevated in adults receiving GH treatment. Next to gender, the heterogeneous aetiology is of influence on mortality in GHD adults with GH treatment.
I N T RO D U C T I O N
Growth hormone deficiency (GHD) in adults has become increasingly recognized as an important (metabolic) syndrome. 1 Patients with adult onset GHD have a decreased life expectancy due to an increased mortality from cardiovascular diseases. 2 Important changes in cardiovascular risk factors, such as adverse lipid profile, increased body mass index, and hypertension in GHD are reported, but also reduced exercise tolerance, osteoporosis, and reduced quality of life. 1; 3 The most common underlying causes of GHD in adults are pituitary adenomas or the consequences of their treatment modalities as surgery and radiotherapy, or craniopharyngiomas. In about one quarter of the adult patients, GHD is of childhood-onset and multiple pituitary hormone deficiencies are present in the majority. [4] [5] [6] The availability of recombinant GH in 1985 has made replacement therapy an option in adults with GHD. Although many patients worldwide have received GH treatment, there are still doubts about the safety aspects. Data on long-term efficacy and safety are limited. Short-term studies have shown beneficial effects on the metabolic profile. 4;7-9 Whether GH treatment has implications for life expectancy remains to be established. One study reported normal mortality in 289 GH treated patients and increased mortality in a relatively older group of hypopituitary patients, both compared to the background population. 10 A report from a large post-marketing surveillance program demonstrated that 1903 GHD adults using long-term GH replacement therapy had similar overall mortality as compared to the background population. 11 Nevertheless, there have been suggestions that GH treatment in childhood could raise mortality risk and the risk on developing malignancies. This last concern has been increased by findings in adults of an association between IGF-1 levels and risk of malignancy, 12 and by a raised risk of malignancy in acromegaly. 13 In this nationwide surveillance study, the Dutch National Registry of Growth Hormone Treatment in Adults, we investigated the effect of GH treatment on mortality in GHD adults from 1985 to 2009. All-cause and cause-specific, e.g. malignancy and CVD, mortality rates were compared to the general Dutch population. Influencing variables on mortality were analysed.
M E T H O D S

Study population
The Dutch National Registry of Growth Hormone Treatment in Adults was established in 1998 as an initiative of the Ministry of Health to gain insight into long-term efficacy, safety, and costs of GH treatment in the Netherlands.
14 Approval of the indication severe GHD by an independent board was required for reimbursement of GH treatment from the health insurer and to this assessment a registry was linked. Severe GHD was defined according to the consensus guidelines of the Growth Hormone Research Society. 15 A GH stimulation test was performed in 85% of cases, combined with an IGF-1 level below -2 SD. Low IGF-1 levels in combination with two or more other pituitary hormone deficits or an evident hypothalamic-pituitary disease was also considered to indicate GHD. All patients were informed by their attending physician. Data was consequently recorded and analysed anonymously. Up to 2009 2891 patients were registered. Their characteristics and diagnostic test procedures are described in more detail elsewhere. 14 For analyses 197 patients were excluded because of a follow-up period of less than 30 days. Patients were subdivided into three groups (figure 1).
132 132 Patients in the treatment group (n=2229) were receiving GH treatment for at least 30 days and at the moment of the most recent data collection. Patients in the primary control group (n=109) were diagnosed with severe GHD, however, for different reasons GH treatment was not commenced or discontinued before 30 days. The reasons for not commencing: unwillingness of the patient or lack of subjective efficacy before 30 days of treatment 36%
, not yet commenced due to short follow-up or loss to follow-up 32%, unknown reason 20%, serious comorbidity (including malignancies and recurrence) 12%. The secondary control group (n=356) consisted of patients that were treated with GH for at least 30 days, but in whom GH treatment was stopped for more than 90 days subsequently. The reasons for discontinuation: unwillingness of the patient or lack of subjective efficacy 41%, minor adverse events (including oedema, joint or muscle pain or stiffness) 29%, major adverse events (including recurrence, growth of tumor, de novo malignancy) 26%, unknown reason 4%. Most patients (89.3%) had multiple pituitary hormone deficiencies and when required, received adequate replacement therapy. Of patients, who were diagnosed with GHD in childhood; approximately 95% was treated with GH before registration.
Measurements
Data was collected from medical records by trained monitors on a paper case report form and checked before entry into the database and afterwards. As an internal quality control, in 10% of patients, data was collected twice by different monitors. When GH treatment was started before the first monitor visit, data were collected retrospectively. The dose of GH was individualized by the attending physician with the common aim of normalizing IGF-1 SD scores. Every change in GH dosage was recorded and the mean dose per patient was calculated as the cumulative dosage divided by the total of days that GH was administered. Date and cause of death were collected through medical records and death certification from the Dutch Central Bureau of Statistics. Cardiovascular disease (CVD) was defined as International Classification of Disease, 10 th Revision (ICD-10) codes I20-I79 (including cerebrovascular accidents (CVA) I60-I69). Malignancies were defined as codes C00-D48. Person-years of observation were calculated from the date of starting GH treatment in adulthood (baseline) until the last date of follow-up or date of death. When GH treatment was not commenced, observation started from the date of confirmation of the diagnosis in adulthood. When GH treatment was not ceased for retesting, observation started from the date of registration. Patients lost to follow-up were censored in the analyses. Expected mortality was calculated from national death and population counts obtained from the Central Bureau of Statistics.
Statistical analyses
Categorical data are expressed as number (percentage) and continuous data as mean (SD), or as median (interquartile range (IQR)) for skewed variables. Continuous variables were compared by ANOVA and categorical variables by χ 2 test. Two sided P values 0.05 or less were considered significant. A Cox's proportional hazard model was used to evaluate the mortality risk for the control groups compared to the treatment group. Potential confounders were tested and, in case of more than 10% change in regression coefficient, included in the adjusted model together with age and sex. Because of non-linearity age was categorised. Age, sex, onset of GHD (adult-onset (AO) or childhood-onset (CO)), extension of hypopituitarism (isolated GHD or multiple pituitary hormone deficiencies (MPHD)), cranial radiotherapy, GH dose, baseline date (before or after January 1 st 2000, in order to correct for change in comorbidities and their treatment modalities over time), and underlying diagnosis were evaluated. Underlying diagnoses were categorised in five groups, namely non-secreting adenomas, GH-and ACTH-secreting adenomas, craniopharyngiomas, possible malignant cause of hypopituitarism (non-pituitary tumor in pituitary region, (treatment of) brain tumor not in pituitary region and meningiomas), and other causes (e.g. Sheehan's syndrome, congenital or idiopathic GHD). The proportional hazards assumption of constant hazard ratio (HR) over time was tested using scaled Schoenfeld residuals. An interaction with time was demonstrated, resulting in different HR before and after follow-up of 5.5 year. Standardised mortality ratios (SMR) for all-cause and cause-specific mortality were determined for all groups, and stratified by sex. The SMR was calculated as the ratio of observed to the number of expected deaths in the background population. Expected mortality was obtained from cause, sex, calendar year and 5-year age-specific death rates from the CBS. Results are shown with 95% confidence intervals (CI). Within the treatment group SMR was stratified for patient characteristics to investigate independent factors influencing mortality. Heterogeneity tests between strata were made with a χ 2 test. 16 For subsequent analyses, age and underlying diagnosis were dichotomised. Patients with craniopharyngioma or other possible malignant cause of hypopituitarism were defined as high-risk patients. Statistical analyses were performed by the statistical software package SPSS version 15.0 (SPSS Inc., Chicago, IL) and Stata 11 for Windows (Stata Corp., College Station, TX, USA).
R E S U LT S
Baseline characteristics
The 2694 included patients (48.7% female) had a mean age at baseline of 43.5 year (SD 16.5). Table 1 shows the baseline characteristics of the three groups. Demographics of the 197 excluded patients were not significantly different, except for a lower percentage of patients who had received cranial radiotherapy. The median follow-up of the entire cohort was 6.1 year (IQR 6.5). 
All-cause mortality
The person-years of observation for the entire cohort were almost 17.000. Of the 2694 patients 135 (5%) died (44% female) with a median age at death of 62.1 year (IQR 21.6). Figure 2 shows the survival curve of the three groups. The risk on all-cause mortality is significantly increased in the primary, and not in the secondary control group, until 5.5 year of follow-up compared to the treatment group in a Cox regression analysis. Thereafter, the risk on all-cause mortality significantly increases in both groups compared to the treatment group. When adjusting for relevant confounders (age, sex and underlying diagnosis) the HR of the primary control group was 1.89 (CI 0.86-4.13, p=0.11) before and 2.61 (CI 1.06-6.40, p=0.04) after 5.5 year of follow-up. For the secondary control group the HR was 1.05 (CI 0.65-1.68, p=0.86) before and 1.23 (CI 0.72-2.11, p=0.46) after 5.5 year of follow-up. To compare mortality in the different groups to the background population the SMR was calculated. There was an increased SMR in the treatment group, especially in women. Exclusion of patients with former GH-or ACTH-secreting adenoma did not change the results. After exclusion of high-risk patients the SMR was not significantly increased. For women the SMR was higher than for men, but did not reach significance (p=0.08). In the control groups the SMR was not significantly increased compared to the background population (table 2). Cause-specific mortality
In 22 patients data on cause of death could not be recovered. Most patients demonstrated a malignant neoplasm (30%) as primary cause of death. Brain neoplasm was most prevalent, followed by malignancies of the digestive and respiratory system. CVD was the primary cause of death in 26% of patients, of which 31% was due to a CVA. The SMR for malignancy in the treatment group was not 136 136 significantly increased. The SMR for CVD was more than two-fold increased in women compared to the background population. Exclusion of patients with former GH-or ACTH-secreting adenoma did not significantly change the results. After exclusion of high-risk patients the overall SMR for death due to malignancy was significantly lower than the general population. The SMR for death due to CVD remained increased in women. The control groups did not have enough observed events to calculate a reliable SMR (table 3) . In the treatment group the overall SMR for death due to CVA was 2.54 (CI 1.41-4.59), for men 1.97 (CI 0.82-4.73) and women 3.37 (CI 1.51-7.50).
Factors influencing mortality
Within the treatment group, women had a higher SMR compared to men. Patients with CO GHD had an increased mortality compared to the background population. This was significantly higher than patients with AO GHD. Furthermore, patients with a younger age at baseline or underlying diagnosis of craniopharyngioma or other possible malignant cause of hypopituitarism did very poorly (table 4) . With regard to cause-specific mortality in the treatment group the patient characteristics sex, cranial radiotherapy, age at baseline, and underlying diagnosis were further investigated ( figure 3A-D) . Women showed significantly higher SMR for CVD mortality than men. Patients who received radiotherapy had higher mortality due to malignancy and CVA. Patients younger than 45 year or with a high-risk underlying diagnosis demonstrated higher SMR in all cause-specific mortalities. Patients in the treatment group with other than a high-risk underlying diagnosis had an overall SMR for all-cause mortality similar to the general population.
D I S C U S S I O N
This is the first nationwide study on the effect of GH treatment on all-cause and cause-specific mortality in GHD adults. Based on more than 13.000 treatment-years we have demonstrated that GHD adult men receiving GH treatment have a mortality rate not different from the general population. Women have an increased risk, which is lower after exclusion of high-risk patients (craniopharyngioma or other possible malignant causes of hypopituitarism). We found mortality due to malignancy not to be elevated in GHD patients treated with GH. Mortality due to CVD was increased in women, even after exclusion of high-risk patients. Next to sex, onset of GHD, age at baseline, and underlying diagnosis were relevant influencing factors for all-cause mortality in GHD adults receiving GH treatment. For cause-specific mortality, age and underlying diagnosis also demonstrated to be important variables.
Following Rosén and Bengtsson, 2 several studies have demonstrated an increased all-cause and cause-specific mortality in hypopituitary patients compared to the background population. [17] [18] [19] [20] Because of the unfavourable metabolic profile, GHD is occasionally pointed as responsible pituitary deficiency for this increased mortality. 1;21 In our study we were unable to demonstrate an increased SMR for the untreated patients. This could be explained by the small number of registered patients in whom no GH treatment was commenced. Also, the primary control group did contain CO GHD patients who received GH treatment in the past, though only comprising 13%. The mortality risk was higher compared to the treatment group, but it should be kept in mind that this could be subject to bias as comorbidity can be a reason not commencing GH treatment. In the survival curve the secondary control group seemed to diverge from the treatment group at one point when most patients ended treatment. After adjustment for different confounders this effect was not significant. Interpretation of reversibility of GH treatment effect should be done with caution. The reason for ending GH treatment should be taken into account because it is possible this influences survival as well.
To date, only a few studies have investigated the effect of GH treatment on mortality in GHD adults. Svensson et al. 10 studied 289 GH treated adults followed for 1443 patient-years and observed 11 analysed 1903 patients treated for a total of 2334 years and demonstrated a SMR of 0.94 (CI 0.49-1.68). In our larger treatment group, followed for a significant longer period, we have demonstrated a slightly increased SMR for all-cause mortality, more obvious in women than in men. Because GH therapy was available for widespread use in adults after 1985, patients included in our cohort have a wide range of GHD duration before commencing GH treatment. The negative effects of long-time GHD on for instance the cardiovascular risk profile could already been that evident precluding GH treatment's effect on decreasing mortality rate. Future analyses will have to elucidate this notion. After exclusion of high-risk patients, based on underlying diseases, the SMR for all-cause mortality appeared not to differ from the background population. Other studies often exclude patients with former GH-or ACTH-secreting adenomas. Excluding these patients did not change our results.
The effect of GH treatment on cause-specific mortality has not been evaluated. Svensson et al. 10 did show no increased prevalence of malignancies or myocardial infarctions in GH treated adults. There was a trend towards an increased number of CVA compared to the general Swedish population. A study in children having received GH treatment raised some concern on development of malignancies, 22 but other studies were contradicting. 23;24 A recent review on safety aspects of GH treatment in adults reports no increase in cancer risk in a large surveillance study, 25 nor was there an association between cancer and IGF-1 level in GH treated adults. 26 This is in line with our finding on mortality from malignancy in the treatment group. It has to be mentioned that of 15 patients in the treatment group the cause of death was unknown. However, if, of these unknown causes, also 30% was a malignant neoplasm, the overall SMR would still have been normal (33 observed to 32.4 expected deaths). The beneficial effects on cardiovascular risk parameters provided by GH treatment in GHD adults would suggest a reduction in CVD mortality. In our treatment group mortality from CVD is normal in men compared to the background population but significantly elevated in women. Again, exclusion of patients with GH-and ACTH-secreting adenomas did not influence these results. Gender differences in the effects of GH treatment on mortality in GHD adults seem evident. In hypopituitarism a gender difference has been described several times. 17;18;20;27;28 There is data indicating GHD men are more responsive to GH treatment than women with respect to increase in IGF-1 levels and improvement of body composition. 29;30 Differences in estrogen concentrations have been suggested as a possible underlying cause. Also, estrogen replacement in GHD women weakens the IGF-1 response to GH treatment, whereas in men androgen replacement increases the responsiveness. 31 In our study all patients have received GH treatment with individualized dosage depending on IGF-1 values. An interaction between sex steroids and GH in the peripheral tissues, as often hypothesised, cannot be addressed in our study. Of the MPHD patients almost 80% suffered 140 140 gonadal deficiency. In patients with MPHD the SMR was not higher than in patients with isolated GHD. It could be that undertreatment of gonadal deficiency as suggested in other studies, 20;32 together with GHD, has implications for mortality in women, especially due to CVD. Because of little events stratification for extension of hypopituitarism or gonadal substitution could not be analysed for CVD mortality. These important findings though merit more detailed investigations. Adult patients with GHD comprise a heterogeneous group as regard to degree of hypopituitarism as well as underlying disease and its treatment. The high-risk patients resemble the younger group at baseline and both demonstrated the highest all-cause and cause-specific mortality in our treatment group. This is also demonstrated in untreated adults with CO GHD having higher SMR than patients with AO GHD, 33 and younger patients or patients with former craniopharyngioma indicating higher all-cause mortality. 20 GH treatment does not seem to resolve this a priori increased mortality risk, 34 as demonstrated in our study, and previously investigated in patients with former craniopharyngioma on long-term GH treatment. 35 Therefore, more focus on quality of life parameters instead of survival in prescribing GH treatment for these specific patients might be necessary. Two previous studies have found cranial radiotherapy to be a predictor of stroke in hypopituitary patients. 18;20 In our study patients who received cranial radiotherapy had a significantly increased mortality due to CVA compared to the background population and to patients who have not received radiotherapy. The underlying diagnosis, as indication for radiotherapy, is an important factor that should be taken into account. Nevertheless, the stratification for having received cranial radiotherapy did not seem to be distinctive for mortality due to all CVD. This could mean that GH treatment does not provide protection from stroke caused by radiation angiopathy. 36 One of the merits of our study is the inclusion of adults with diagnosed severe GHD as stated in the consensus valid at time of registration.
14 Furthermore, our control groups made it possible to compare the treatment group with Dutch untreated GHD adults and to study reversibility aspects. Nevertheless, because of limitedness of registered patients unlikely to commence GH treatment, no additional analyses could be conducted in this group. Data on cause of death based on medical records and death certification do not ascertain complete accuracy of cause-specific mortality. CVD-related death can be overestimated in the absence of autopsy. 37 However, the reference population was subject to this same bias.
In conclusion, our results demonstrate an increased mortality rate for all-cause mortality in GH treated GHD adults, especially in women with a high mortality due to CVD. A control group of untreated patients of substantial size is needed to fully interpret these findings and answer the question whether GH treatment reduces mortality in GHD adults. The gender difference found elicits the question regarding the influence in women of other pituitary hormone deficiencies or their replacement on mortality in combination with GH treatment. GH treatment appears to be safe in men and women with respect to mortality due to malignancies. The heterogeneous aspect of patients with GHD should be taken into consideration when estimating the effect of GH treatment on mortality.
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